Table 1 Baseline characteristics of the study groups
Characteristics | FMT group (n = 62) | GCs group (n = 60) | p value |
|---|---|---|---|
Gender, n (%) | |||
 Male | 44 (71.7) | 43 (71.7) | 0.93 |
 Female | 18 (28.3) | 17 (28.3) | |
Age, mean (SD) | 43.1 (17.1) | 47.4 (16.2) | 0.16 |
Duration of disease, mean (SD) | 2.7 (3.4) | 3.4 (3.9) | 0.33 |
Disease extent, n (%) | |||
 E1, Proctitis | 13 (21.0) | 11 (18.3) | 0.78 |
 E2, Left-sided colitis | 24 (38.7) | 27 (45) | |
 E3, Pancolitis | 25 (40.3) | 22 (36.7) | |
Concomitant medicine, n (%) | |||
 Oral 5-ASA | 62 (100) | 60 (100) |  |
 Topical 5-ASA | 0 | 0 |  |
 Immunomodulator | 0 | 0 |  |
 Biologics | 0 | 0 |  |
Total Mayo scores | |||
 Mean (SD) | 6.8 (1.9) | 7.2 (2.0) | 0.33 |
 Range | (4–10) | (4–10) | |
Endoscopic Mayo scores | |||
 Mean (SD) | 2.2 (0.6) | 2.0 (0.6) | 0.10 |
 Range | (1–3) | (1–3) | |
Inflammatory index | |||
 WBC count, × 109/L, mean (SD) | 7.0 (2.4) | 6.9 (2.5) | 0.82 |
 Neutrophils count, × 109/L, mean (SD) | 4.6 (2.2) | 4.6 (2.0) | 0.99 |
 CRP, mg/L, median (IQR) | 2.5 (0.7–7.9) | 4.6 (0.8–12.8) | 0.12 |
 ESR, MM/H, median (IQR) | 11 (5–25) | 15 (5–37.3) | 0.39 |
 PLT count, × 109/L, mean (SD) | 256.8 (83.9) | 250.5 (78.2) | 0.66 |
 Hemoglobin, g/L, mean (SD) | 132.2 (19.5) | 126.1 (23.4) | 0.12 |
 Albumin, g/L, mean (SD) | 40.9 (5.2) | 39.5 (5.6) | 0.17 |